Dissemination and Adoption of Comparative Effectiveness Research Findings When Findings Challenge Current Practices. New Evidence Following Initial Release of CATIE Results


Additional results from CATIE and similar trials have consistently supported CATIE’s initial findings. Findings from quality-of-life and neurocognitive substudies showed only marginal improvements across treatment groups, with no significant differences between groups. In 2006, a cost-effectiveness analysis using CATIE data found that the additional cost of atypical antipsychotics was not justified given the similar effectiveness of the first- and second-generation treatments. A second trial that compared the effectiveness of first- and second-generation medications in the United Kingdom, the CUTLASS trial, was released in 2006 and confirmed the results of CATIE across most outcomes. A paper released in 2010 showed that the incidence of tardive dyskinesia has remained relatively constant since the 1980s, despite the widespread shift to second-generation medications (Woods, Morgenstern, et al., 2010). These findings reinforce the conclusion that the initial concerns about the extrapyramidal side effects of first-generation medications were overblown.

View full report


"rpt_RANDFinal.pdf" (pdf, 2.01Mb)

Note: Documents in PDF format require the Adobe Acrobat Reader®. If you experience problems with PDF documents, please download the latest version of the Reader®